GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy
GI Innovation and GI Biome have been selected as a Top 40 semi- finalist in the XPRIZE Healthspan competition among 600 registered teams from 58 countries Selected as one of 8 teams to pitch at the XPRIZE Investor Summit in New York The team is now...
GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy
SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy. From...